急性髓系白血病化疗后NPM1突变分子持续阳性的临床影响
抢先挽救治疗显著延长无复发生存,诊断时合并FLT3-ITD及结束治疗时MRD缓解不佳与疾病进展相关。
要点
- 抢先挽救治疗显著延长无复发生存。
- 诊断时FLT3-ITD及MRD下降<4.4-log与疾病进展相关。
核心结论
- 结束治疗时NPM1突变MRD持续阳性患者中部分可自发清除或维持低水平,抢先挽救治疗可显著延长无复发生存。
主要发现
- 42%的患者1年时无进展,其中30%自发达到完全分子学缓解(CRMRD-),12%维持低水平NPM1突变转录本≥12个月,9%在末次随访时仍维持。
- 抢先挽救治疗显著延长无复发生存。
- 诊断时合并FLT3-ITD及结束治疗时NPM1突变下降<4.4-log是与疾病进展相关的危险因素。
关键数值与推荐
- MP-LCN定义为结束治疗(EOT)后任意2份阳性样本间MRD转录本水平<1%至2%且变化<1-log。
- MRD缓解不佳定义为EOT时NPM1突变下降<4.4-log。
临床怎么用
- 对强化化疗后EOT时NPM1突变MRD阳性的AML患者,应评估是否符合MP-LCN并识别FLT3-ITD等高危因素。
- 抢先挽救治疗可考虑用于延长无复发生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level <1% to 2% with a <1-log change between any 2 positive samples collected after the end of treatment (EOT). Because the clinical impact of MP-LCN is unknown, we sought to characterize outcomes in patients with persistent NPM1mut MRD after EOT and identify factors associated with disease progression. Consecutive patients with newly diagnosed NPM1mut AML who received ≥2 cycles of intensive chemotherapy were included if bone marrow was NPM1mut MRD positive at the EOT, and they were not transplanted in first complete remission. One hundred patients were followed for a median of 23.5 months; 42% remained free of progression at 1 year, either spontaneously achieving complete molecular remission (CRMRD-; 30%) or retaining a low-level NPM1mut transcript (12% for ≥12 months and 9% at last follow-up). Forty percent met the criteria for MP-LCN. Preemptive salvage therapy significantly prolonged relapse-free survival. Risk factors associated with disease progression were concurrent FLT3-internal tandem duplication at diagnosis and suboptimal MRD response (NPM1mut reduction <4.4-log) at EOT.
引用
- Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021. PMID: 34555849. doi:10.1182/bloodadvances.2021005455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。